KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $1.8 billion.

  • Regeneron Pharmaceuticals' Other Non-Current Assets rose 6031.69% to $1.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 billion, marking a year-over-year increase of 6031.69%. This contributed to the annual value of $1.8 billion for FY2025, which is 6031.69% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Other Non-Current Assets is $1.8 billion, which was up 6031.69% from $1.7 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $1.8 billion during Q4 2025, with a 5-year trough of $142.9 million in Q2 2021.
  • For the 5-year period, Regeneron Pharmaceuticals' Other Non-Current Assets averaged around $675.2 million, with its median value being $401.5 million (2023).
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Other Non-Current Assets plummeted by 1857.55% in 2021, and later soared by 19627.82% in 2025.
  • Regeneron Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $216.1 million in 2021, then soared by 55.67% to $336.4 million in 2022, then skyrocketed by 32.02% to $444.1 million in 2023, then surged by 155.8% to $1.1 billion in 2024, then skyrocketed by 60.32% to $1.8 billion in 2025.
  • Its Other Non-Current Assets was $1.8 billion in Q4 2025, compared to $1.7 billion in Q3 2025 and $1.5 billion in Q2 2025.